| | Conflict of Interest |
William F. Balistreri, MD, receives research funding from the National Institutes of Health. |
Stephen R. Daniels, MD, PhD, serves as a consultant for Abbott Laboratories and Merck, Schering-Plough. |
Alan H. Jobe, MD, PhD, participated in studies in Western Australia that receive support (funding and research equipment) from Fisher and Paykel, New Zealand, and partial support form NICHD (no direct funding from either), receives donations of surfactant for animal studies that are performed in Western Australia from Chiesi, Parma, Italy, and has given talks at educational symposia funded by unrestricted educational grants from Chiesi (received no direct payment other than reimbursement for expenses). |
Sarah S. Long, MD, declares no conflicts of interest, real or perceived, financial or nonfinancial. |
Thomas R. Welch, MD, declares no conflicts of interest, real or perceived, financial or nonfinancial. |
Robert W. Wilmott, MD, declares no conflicts of interest, real or perceived, financial or nonfinancial. |
Monica L. Helton, BA, declares no conflicts of interest, real or perceived, financial or nonfinancial. |
Steven H. Abman, MD, has advised Ikaria on an educational project that has been completed (no ongoing financial relationship) and received a laboratory grant from Bayer HealthCare for research. |
Pasquale J. Accardo, MD, declares no conflicts of interest, real or perceived, financial or nonfinancial. |
Hans C. Andersson, MD, FACMG, services as an expert in metabolic diseases for Genzyme Corp., Biomarin, and Amicus. |
Sharon P. Andreoli, MD, reviews grants for the National Institutes of Health and Genentech. |
William L. Carroll, MD, declares no conflicts of interest, real or perceived, financial or nonfinancial. |
Ronald I. Clyman, MD, has received an unrestricted research grant from Ovation Pharmaceuticals. |
Paul H. Dworkin, MD, declares no conflicts of interest, real or perceived, financial or nonfinancial. |
Paul G. Fisher, MD, serves on the Data Monitoring Committee for Merck (MK-462; Maxalt, a migraine medicine) and the speakers bureau for Enzon Pharamceuticals (liposomal cytarabine Depocyt, a chemotherapy drug). |
John G. Frohna, MD, MPH, declares no conflicts of interest, real or perceived, financial or nonfinancial. |
Samuel S. Gidding, MD, declares no conflicts of interest, real or perceived, financial or nonfinancial. |
Thomas P. Green, MD, declares no conflicts of interest, real or perceived, financial or nonfinancial. |
Terrie E. Inder, MD, declares no conflicts of interest, real or perceived, financial or nonfinancial. |
M. Susan Jay, MD, declares no conflicts of interest, real or perceived, financial or nonfinancial. |
Nancy F. Krebs, MD, MS, declares no conflicts of interest, real or perceived, financial or nonfinancial. |
Wayne J. Morgan, MD, serves as a consultant for Novartis (2009-2010; non-recurring), Chair of the Data Safety Monitoring Board, which is funded by the Cystic Fibrosis Foundation ($150 000 yearly grant; $32 000 for consultancy in 2009), Chair of the North American Scientific Advisory Board for the Epidemiologic Study of Cystic Fibrosis, which is funded by Genentech ($5000-7500 per year over the last 5 years), and receives research grant funding from the National Institutes of Health, National Institutes of Allergy and Infectious Diseases, and National Heart, Lung, and Blood Institute (over $10 000). |
James F. Padbury, MD, declares no conflicts of interest, real or perceived, financial or nonfinancial. |
Alan D. Rogol, MD, PhD, serves on the Scientific Advisory Boards for Genentech, Inc., Pfizer, Inc., and Dean Foods and as a consultant for Insmed, Inc., Tercica, Inc., and Solvay, Inc. |
Lainie Friedman Ross, MD, PhD, serves as an expert witness for Kennedy Krieger Institute and Johns Hopkins Medical Institute for lead research done in the 1990s. |
Janet H. Silverstein, MD, serves on the Nutropin Advisory Board for Genentech (grant review), conducting research with Pfizer, and participating in growth hormone registries with Genentech, Lilly, and Pfizer. |
Kristen Stahl, MD, declares no conflicts of interest, real or perceived, financial or nonfinancial. |
Marshall L. Summar, MD, declares that Vanderbilt University has filed for patents on his behalf for the use of citrulline in clinical applications. |
Philip Toltzis, MD, has research contracts with Viropharma Pharmaceuticals and BASF. |
Russell E. Ware, MD, PhD, serves as a consultant for Glycomimetics, Inc. |
Reginald L. Washington, MD, declares no conflicts of interest, real or perceived, financial or nonfinancial. |
Clyde Wright, MD, declares no conflicts of interest, real or perceived, financial or nonfinancial. |
A. David Edwards, FMedSci, declares no conflicts of interest, real or perceived, financial or nonfinancial. |
Albert M. Li, MD, serves as a member of the Asia Pacific Pediatric Sleep Alliance, which receives an educational grant from Johnson & Johnson, to formulate policy and carry out research in relation to childhood sleep disorder. |
Empar Lurbe, MD, declares no conflicts of interest, real or perceived, financial or nonfinancial. |
Philip M. Sherman, MD, serves as Co-Editor-In-Chief for Functional Food Reviews, the Editorial Board for the Journal of Infectious Diseases, the Research Advisory Board for Antibe Therapeutics (stockholder), the Educational Advisory Board for In Sinc Consultants (honorarium), the Scientific Advisory Boards for NIH Pediatric Gastroenterology Digestive Health Center, University of Cincinnati College of Medicine (honorarium) and Alberta Heritage Foundation for Medical Research, Alberta Inflammatory Bowel Disease Consortium (honorarium), and the Medical Advisory Boards for Astra Zeneca (honorarium), Abbott Nutritionals (honorarium), Mead Johnson (honorarium), and Nestle Nutrition (honorarium) |
|
| |
|
